Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;25(1):973-984.
doi: 10.1080/10717544.2018.1461280.

Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes

Affiliations

Localized delivery of therapeutic doxorubicin dose across the canine blood-brain barrier with hyperthermia and temperature sensitive liposomes

Amy Lee Bredlau et al. Drug Deliv. 2018 Nov.

Abstract

Most drugs cannot penetrate the blood-brain barrier (BBB), greatly limiting the use of anti-cancer agents for brain cancer therapy. Temperature sensitive liposomes (TSL) are nanoparticles that rapidly release the contained drug in response to hyperthermia (>40 °C). Since hyperthermia also transiently opens the BBB, we hypothesized that localized hyperthermia can achieve drug delivery across the BBB when combined with TSL. TSL-encapsulated doxorubicin (TSL-Dox) was infused intravenously over 30 min at a dose of 0.94 mg/kg in anesthetized beagles (age ∼17 months). Following, a hyperthermia probe was placed 5-10 mm deep through one of four 3-mm skull burr holes. Hyperthermia was performed randomized for 15 or 30 min, at either 45 or 50 °C. Blood was drawn every 30 min to measure TSL-Dox pharmacokinetics. Nonsurvival studies were performed in four dogs, where brain tissue at the hyperthermia location was extracted following treatment to quantify doxorubicin uptake via high-performance liquid chromatography (HPLC) and to visualize cellular uptake via fluorescence microscopy. Survival studies for 6 weeks were performed in five dogs treated by a single hyperthermia application. Local doxorubicin delivery correlated with hyperthermia duration and ranged from 0.11 to 0.74 μg/g of brain tissue at the hyperthermia locations, with undetectable drug uptake in unheated tissue. Fluorescence microscopy demonstrated doxorubicin delivery across the BBB. Histopathology in Haematoxylin & Eosin (H&E) stained samples demonstrated localized damage near the probe. No animals in the survival group demonstrated significant neurological deficits. This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits.

Keywords: Thermosensitive liposomes; blood–brain barrier; doxorubicin; hyperthermia; liposomes; thermal therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Intended drug delivery paradigm: (A) BBB is locally opened (indicated by dashed vessel walls) in the region where hyperthermia is applied. (B) Drug (triangles) is released from TSL (circles) in region where BBB is opened, facilitating localized drug delivery across the BBB.
Figure 2.
Figure 2.
The four locations where hyperthermia was applied are indicated by fiducial markers (white arrows) in this X-ray image. The hyperthermia probe was placed through burr holes, penetrating ∼10–15 mm deep into brain tissue.
Figure 3.
Figure 3.
TSL release kinetics. (A) Doxorubicin is almost completely released within ∼2 s when TSL are heated to above 41 °C. (B) TSL stability at body temperature: Approximately 35% of drug is released at 37 °C within the first 5 min, but remaining drug remains stable within TSL.
Figure 4.
Figure 4.
Hyperthermia probe temperature maps measured in vitro in gel phantoms. (A) Temperature maps after 3 min heating are plotted at 45 (left) and 50 °C (right) [probe tip at bottom; in animal studies, only the distal 15 mm was inserted into tissue (arrows)]. (B) Radial temperature profile ∼7 mm from the probe tip for 45 and 50 °C. Temperatures exceeding 41 °C (i.e. where doxorubicin release from TSL is expected) extend ∼4 and ∼6 mm from the probe for 45 and 50 °C, respectively. In vivo, these distances are likely somewhat reduced since blood perfusion-mediated cooling limits temperature spread into tissue.
Figure 5.
Figure 5.
(A) Plasma PK for four animals in the nonsurvival study. Dog 3 had slightly higher body temperature (∼38 °C) during anesthesia than intended, explaining the considerably lower plasma drug concentration that likely resulted from premature systemic drug leakage from the TSL. (B) Plasma PK for five animals in the survival study, where only two plasma samples following drug infusion were obtained in each animal.
Figure 6.
Figure 6.
Tissue doxorubicin concentration separated by hyperthermia condition. There was a trend toward larger drug concentration at both higher temperatures and longer durations, but these did not reach statistical significance.
Figure 7.
Figure 7.
Fluorescence microscopy demonstrates localized doxorubicin delivery to tissue regions surrounding the hyperthermia probe (50 °C, 30 min).
Figure 8.
Figure 8.
Plasma concentration area under the curve (AUC) predicts tissue drug uptake. (A) AUC was calculated based on plasma concentration measured in each particular animal, during the time when hyperthermia was applied. The four shaded regions represent the plasma AUC’s corresponding to the four hyperthermia applications in dog 1 (15, 30, 15, and 30 min, respectively; this sequence varied among animals per Table 2). (B) Plasma AUC calculated during hyperthermia correlates with tissue drug concentration. Each marker represents a tissue sample where drug concentration was measured, plotted against plasma AUC calculated when hyperthermia was applied for that particular sample and animal. Marker color indicates hyperthermia temperature of 45 °C (blue) or 50 °C (red); marker shape represents duration of 15 min (triangles) or 30 min (squares). Dashed lines represent linear fits for each of the two temperature data sets as used in the statistical model B. Plasma AUC was a statistically significant predictor (p = .003) of tissue drug concentration, and temperature trended toward statistical significance (p = .07).
Figure 9.
Figure 9.
(A) Higher temperature and longer hyperthermia duration resulted in increased area of cerebral damage, measured from gross sectioned tissue in acute animals. (B) There is a defect in both brains, but to a lesser extent in animal exposed to 45 °C (tip of white arrow head). In animals exposed to 50 °C, there is a gross cavity within cerebral parenchyma and an associated expansion of the dura mater (black arrow). (C) Histology damage assessment. Both images are at 100× magnification and represent the ventral aspect of the probe insertion site. There is less damage to the surrounding parenchyma in the dog exposed to 45 °C (left) compared to 50 °C (right). Animals exposed to 50 °C had increased hemorrhage, vacuolization (clear spaces), and inflammatory response. Scale bar is 100 μm.

Similar articles

Cited by

References

    1. Aoki H, Kakinuma K, Morita K, et al. (2004). Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia 20:595–605. - PubMed
    1. Brouckaert P, Takahashi N, van Tiel ST, et al. (2004). Tumor necrosis factor-α augmented tumor response in b16bl6 melanoma-bearing mice treated with stealth liposomal doxorubicin (doxil®) correlates with altered doxil® pharmacokinetics. Int J Cancer 109:442–8. - PubMed
    1. Burke C, Dreher MR, Negussie AH, et al. (2017). Drug release kinetics of temperature sensitive liposomes measured at high-temporal resolution with a millifluidic device. Int J Hyperthermia. [Epub ahead of print]. doi:10.1080/02656736.2017.1412504 - DOI - PMC - PubMed
    1. Carpentier A, Canney M, Vignot A, et al. (2016). Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med 8:343re2. - PubMed
    1. CBTRUS (2017). Central brain tumor registry of the United States. Available at: http://www.cbtrus.org [Last accessed Dec 2017]

LinkOut - more resources